Page last updated: 2024-08-22

yttrium and sorafenib

yttrium has been researched along with sorafenib in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Abou-Alfa, GK; Geschwind, JF; Krishnan, S; Salem, R; Schwarz, RE; Venook, AP1
Burak, KW; Thomas, MB; Zhu, AX1
Bulla, K; Kolligs, F; Malfertheiner, P; Peck-Radosavljevic, M; Reimer, P; Ricke, J; Sangro, B; Schott, E; Schütte, K; Verslype, C; Walecki, J1

Trials

1 trial(s) available for yttrium and sorafenib

ArticleYear
Safety and toxicity of radioembolization plus Sorafenib in advanced hepatocellular carcinoma: analysis of the European multicentre trial SORAMIC.
    Liver international : official journal of the International Association for the Study of the Liver, 2015, Volume: 35, Issue:2

    Topics: Carcinoma, Hepatocellular; Combined Modality Therapy; Embolization, Therapeutic; Europe; Follow-Up Studies; Liver Neoplasms; Microspheres; Niacinamide; Phenylurea Compounds; Portal Vein; Sorafenib; Treatment Outcome; Yttrium

2015

Other Studies

2 other study(ies) available for yttrium and sorafenib

ArticleYear
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus statement.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium

2010
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.
    HPB : the official journal of the International Hepato Pancreato Biliary Association, 2010, Volume: 12, Issue:5

    Topics: Antineoplastic Agents; Benzenesulfonates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Consensus Development Conferences as Topic; Hepatectomy; Humans; Liver Neoplasms; Liver Transplantation; Neoplasm Staging; Niacinamide; Patient Selection; Phenylurea Compounds; Practice Guidelines as Topic; Protein Kinase Inhibitors; Pyridines; Radiopharmaceuticals; Radiotherapy; Sorafenib; Treatment Outcome; Yttrium

2010